This article is part of the supplement: Current and new antitumor necrosis factor agents in perspective
Closing remarks
Arthritis Res Ther 2004, 6(Suppl 2):S44 doi:10.1186/ar998
Accesses
- Last 30 days: 10 accesses
- Last 365 days: 187 accesses
- All time: 1461 accesses

